Lista de obras -

A Krukenberg Tumor from an Occult Intramucosal Gastric Carcinoma Identified during an Autopsy

artículo científico publicado en 2014

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

artículo científico publicado en 2020

ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve "Precision Onco-Surgery" in Resectable Colorectal Liver Metastases

artículo científico publicado en 2021

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.

artículo científico publicado en 2018

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

scientific article published on 17 July 2020

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

artículo científico publicado en 2020

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

artículo científico publicado en 2020

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

scholarly article by Saori Mishima et al published 31 January 2019 in Journal for Immunotherapy of Cancer

Correction to: Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

artículo científico publicado en 2020

Detection of presumed germline pathogenic variants of hereditary breast cancer predisposition genes in circulating tumor DNA: SCRUM-Japan MONSTAR-SCREEN.

scientific article published on 06 June 2022

Development of circulating tumour DNA analysis for gastrointestinal cancers

scientific article published on 01 January 2020

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer

scientific article published on 16 March 2020

Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

scientific article published on 25 September 2019

Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC

artículo científico publicado en 2021

FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

artículo científico publicado en 2020

Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities

artículo científico publicado en 2022

Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

artículo científico publicado en 2019

Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

scientific article published in 2022

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer

artículo científico publicado en 2020

Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project

artículo científico publicado en 2021

Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

artículo científico publicado en 2020

O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN

PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

scientific article published on 26 April 2019

PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN

Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens

artículo científico publicado en 2021

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

scientific article published on 09 January 2019

Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer

artículo científico publicado en 2020

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

artículo científico publicado en 2018

Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?", by Marino, Elisabetta et al

artículo científico publicado en 2019

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

scientific article published on 27 December 2019

SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

scientific article published on 19 November 2018

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway

artículo científico publicado en 2017

The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer

scientific article published on 10 March 2020

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer.

artículo científico publicado en 2018

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis

artículo científico publicado en 2020

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined an

artículo científico publicado en 2020

Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis

artículo científico publicado en 2020

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

scientific article published on 04 August 2019

Lista de obras de

A Krukenberg Tumor from an Occult Intramucosal Gastric Carcinoma Identified during an Autopsy

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve "Precision Onco-Surgery" in Resectable Colorectal Liver Metastases

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Correction to: Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

Detection of presumed germline pathogenic variants of hereditary breast cancer predisposition genes in circulating tumor DNA: SCRUM-Japan MONSTAR-SCREEN.

Development of circulating tumour DNA analysis for gastrointestinal cancers

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer

Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC

FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities

Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer

Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project

Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN

PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN

Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?", by Marino, Elisabetta et al

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway

The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer.

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined an

Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel